AR047367A1 - Compuestos de tiourea sustituidos con azabenzofurano, inhibidores de replicacion viral - Google Patents
Compuestos de tiourea sustituidos con azabenzofurano, inhibidores de replicacion viralInfo
- Publication number
- AR047367A1 AR047367A1 ARP050100026A ARP050100026A AR047367A1 AR 047367 A1 AR047367 A1 AR 047367A1 AR P050100026 A ARP050100026 A AR P050100026A AR P050100026 A ARP050100026 A AR P050100026A AR 047367 A1 AR047367 A1 AR 047367A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- amino
- substituted
- haloalkoxy
- haloalkyl
- Prior art date
Links
- 229940123627 Viral replication inhibitor Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 5
- 125000001188 haloalkyl group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 4
- -1 hydroxy, cyano, nitro, amino, acetyl Chemical group 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000005431 alkyl carboxamide group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 125000005392 carboxamide group Chemical class NC(=O)* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea group Chemical group NC(=S)N UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente se refiere a compuestos de tiourea sustituidos con azabenzofurano inhibidores de replicacion viral, composiciones farmacéuticas que los contienen y usos para tratar infecciones virales, particularmente infecciones por HCV.. Reivindicacion 1:Un compuesto de formula (1) o una sal farmacéuticamente aceptable del mismo, caracterizado porque: X y W son independientemente O, S, NR, o están ausentes, en donde R es H, alquilo C1-6 opcionalmente sustituido, o (arilo)alquilo C0-4 opcionalmente sustituido; V es alquilo C1-6, alquenilo C2-6, cicloalquilo C3-7, o está ausente; Y es alquilo C1-6, alquilo C1-6 sustituido con cicloalquilo C3-7, alquenilo C2-6, cicloalquilo C3-7, o está ausente; en donde cuando V está ausente. W está ausente; A1 es N o CR1; A2 es N o CR2; A3 es N o CR3; A4 es N o CR4; en donde 1 o 2 de A1, A2, A3 o A4 es N; R1-R4, cuando están presentes, son seleccionados independientemente entre: (i) H, halogeno, hidroxi, ciano, nitro, amino, acetilo, -NHCO2, -NHSO2, haloalquilo C1-2, y haloalcoxi C1-2, y (ii) alquilo C1-6, alquenilo 2-6, alquinilo C2-6, alcoxi C1-6, mono- y di-(alquilo C1-6)amino, alcanoilo C2-6, alquiltio C1-4, alquilsulfinilo C1-4, alquilsulfonilo C1-4, alquilcarboxamida C1-4, mono- y di-(alquilo C1-4)carboxamida, (cicloalquilo C3-8)alquilo C0-2, heterocicloalquilo C2-7, monocíclico, fenilo, piridilo, y pirimidinilo; cada uno de los cuales es sustituidos con 0 a 5 sustituyentes seleccionados independientemente entre halogeno, hidroxi, alquilo C1-4, alcoxi C1-4, mono- y di-(alquilo C1-4)amino, haloalquilo C1-2, y haloalcoxi C1-2; R5 es H, halogeno, hidroxi, amino, nitro, ciano, alquilo C1-4, alcoxi C1-4, haloalquilo C1-2, o haloalcoxi C1- 2; r6 y R7 son independientemente H, o R6 y R7 son independientemente alquilo C1-6, alquenilo C2-6, o alquinilo C2-6, cada uno de los cuales está sustituido con 0 a 3 sustituyentes seleccionados independientemente entre halogeno, hidroxi, amino, alcoxi C1-4, haloalquilo C1-2, y haloalcoxi C1-2, o R6 y R7 están unidos para formar un anillo heterocíclico saturado o mono-insaturado de 5 a 7 miembros que contiene opcionalmente un heteroátomo adicional seleccionado entre N, S, y O, anillo heterocíclico saturado o mono-insaturado de 5 a 7 miembros que está sustituido con 0 a 3 sustituyentes seleccionados independientemente entre halogeno, hidroxi, amino, alquilo C1-4, alcoxi C1-4, mono- y di-(alquilo C1-4)amino, haloalquilo C1-2, y haloalcoxi C1-2; y Ar es arilo opcionalmente sustituido o heteroarilo opcionalmente sustituido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53483904P | 2004-01-06 | 2004-01-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR047367A1 true AR047367A1 (es) | 2006-01-18 |
Family
ID=34794326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050100026A AR047367A1 (es) | 2004-01-06 | 2005-01-05 | Compuestos de tiourea sustituidos con azabenzofurano, inhibidores de replicacion viral |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7439374B2 (es) |
| EP (1) | EP1709047B1 (es) |
| JP (1) | JP2007517887A (es) |
| KR (1) | KR20060121289A (es) |
| CN (1) | CN1946720A (es) |
| AP (1) | AP2006003659A0 (es) |
| AR (1) | AR047367A1 (es) |
| AT (1) | ATE479684T1 (es) |
| AU (1) | AU2005204369B2 (es) |
| BR (1) | BRPI0506705A (es) |
| CA (1) | CA2552002A1 (es) |
| DE (1) | DE602005023266D1 (es) |
| EA (1) | EA200601281A1 (es) |
| IL (1) | IL176486A0 (es) |
| NO (1) | NO20062928L (es) |
| NZ (1) | NZ548375A (es) |
| OA (1) | OA13357A (es) |
| TW (1) | TW200528459A (es) |
| WO (1) | WO2005067900A2 (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200600492A (en) * | 2004-05-18 | 2006-01-01 | Achillion Pharmaceuticals Inc | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication |
| TWI329102B (en) * | 2006-08-15 | 2010-08-21 | Nat Health Research Institutes | Thiourea compounds and method for inhibiting hepatitis c virus infection |
| US20080182895A1 (en) * | 2006-08-25 | 2008-07-31 | Howe Anita Y M | Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| WO2008124300A1 (en) * | 2007-04-10 | 2008-10-16 | National Health Research Institutes | Hepatitis c virus inhibitors |
| WO2008154091A1 (en) * | 2007-06-08 | 2008-12-18 | National Health Research Institutes | Thiourea derivatives |
| TWI361808B (en) * | 2008-01-08 | 2012-04-11 | Nat Health Research Institutes | Imidazolidinone and imidazolidinethione derivatives |
| US8198284B2 (en) * | 2008-04-30 | 2012-06-12 | National Health Research Institutes | Treatment of neurodegenerative disorders with thiourea compounds |
| US8198449B2 (en) * | 2008-09-11 | 2012-06-12 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| PA8855601A1 (es) | 2008-12-23 | 2010-07-27 | Forformidatos de nucleósidos | |
| US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
| US8716263B2 (en) | 2008-12-23 | 2014-05-06 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| PL3290428T3 (pl) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu |
| JP5872539B2 (ja) | 2010-03-31 | 2016-03-01 | ギリアド ファーマセット エルエルシー | プリンヌクレオシドホスホルアミダート |
| WO2011123668A2 (en) | 2010-03-31 | 2011-10-06 | Pharmasset, Inc. | Stereoselective synthesis of phosphorus containing actives |
| AR082453A1 (es) | 2010-04-21 | 2012-12-12 | Novartis Ag | Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos |
| EP2646453A1 (en) | 2010-11-30 | 2013-10-09 | Gilead Pharmasset LLC | Compounds |
| SMT201800087T1 (it) | 2011-09-16 | 2018-03-08 | Gilead Pharmasset Llc | Metodi per trattare hcv |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| CN103467482B (zh) * | 2012-04-10 | 2017-05-10 | 上海璎黎药业有限公司 | 稠合嘧啶类化合物，其制备方法，中间体，组合物和应用 |
| EA029081B9 (ru) | 2013-01-31 | 2018-09-28 | Джилид Фармассет Ллс | Комбинированный состав двух противовирусных соединений |
| PL3038601T3 (pl) | 2013-08-27 | 2020-08-24 | Gilead Pharmasset Llc | Formulacja złożona dwóch związków przeciwwirusowych |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| CN114539273A (zh) | 2016-06-07 | 2022-05-27 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| HRP20241239T1 (hr) | 2017-03-23 | 2024-12-06 | Jacobio Pharmaceuticals Co., Ltd. | Novi heterociklički derivati korisni kao shp2 inhibitori |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| WO2020063760A1 (en) | 2018-09-26 | 2020-04-02 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2150834B1 (es) | 1971-08-23 | 1975-10-17 | Medizinska Akad | |
| CN1071930A (zh) | 1991-07-10 | 1993-05-12 | 伊莱利利公司 | 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂 |
| GB9504460D0 (en) | 1995-03-06 | 1995-04-26 | Bayer Ag | N-(3-Benzofuranyl)urea-derivatives |
| JP2000510833A (ja) | 1996-05-06 | 2000-08-22 | イーライ・リリー・アンド・カンパニー | 抗―ウイルス性化合物群 |
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| AU2003290584B2 (en) | 2002-11-01 | 2009-07-16 | Viropharma Incorporated | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases |
| AP2005003319A0 (en) | 2002-11-19 | 2005-06-30 | Achillion Pharmaceitucals Inc | Substituted aryl thioureas and related compounds; inhibitors of viral replication |
| KR20070007759A (ko) * | 2003-07-10 | 2007-01-16 | 아칠리온 파르마세우티칼스 인코포레이티드 | 바이러스 복제 억제제로서 유용한 치환된 아릴티오우레아유도체 |
-
2004
- 2004-12-30 TW TW093141409A patent/TW200528459A/zh unknown
-
2005
- 2005-01-05 WO PCT/US2005/000339 patent/WO2005067900A2/en not_active Ceased
- 2005-01-05 AR ARP050100026A patent/AR047367A1/es not_active Application Discontinuation
- 2005-01-05 BR BRPI0506705-7A patent/BRPI0506705A/pt not_active IP Right Cessation
- 2005-01-05 AT AT05705124T patent/ATE479684T1/de not_active IP Right Cessation
- 2005-01-05 EP EP05705124A patent/EP1709047B1/en not_active Expired - Lifetime
- 2005-01-05 CN CNA200580007223XA patent/CN1946720A/zh active Pending
- 2005-01-05 AP AP2006003659A patent/AP2006003659A0/xx unknown
- 2005-01-05 DE DE602005023266T patent/DE602005023266D1/de not_active Expired - Lifetime
- 2005-01-05 NZ NZ548375A patent/NZ548375A/en unknown
- 2005-01-05 US US11/029,910 patent/US7439374B2/en not_active Expired - Fee Related
- 2005-01-05 OA OA1200600222A patent/OA13357A/en unknown
- 2005-01-05 JP JP2006549390A patent/JP2007517887A/ja active Pending
- 2005-01-05 CA CA002552002A patent/CA2552002A1/en not_active Abandoned
- 2005-01-05 KR KR1020067013660A patent/KR20060121289A/ko not_active Withdrawn
- 2005-01-05 AU AU2005204369A patent/AU2005204369B2/en not_active Ceased
- 2005-01-05 EA EA200601281A patent/EA200601281A1/ru unknown
-
2006
- 2006-06-21 IL IL176486A patent/IL176486A0/en unknown
- 2006-06-22 NO NO20062928A patent/NO20062928L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005204369A1 (en) | 2005-07-28 |
| NO20062928L (no) | 2006-08-03 |
| EA200601281A1 (ru) | 2006-12-29 |
| BRPI0506705A (pt) | 2007-05-02 |
| IL176486A0 (en) | 2006-10-05 |
| US20050228013A1 (en) | 2005-10-13 |
| EP1709047B1 (en) | 2010-09-01 |
| DE602005023266D1 (de) | 2010-10-14 |
| ATE479684T1 (de) | 2010-09-15 |
| CA2552002A1 (en) | 2005-07-28 |
| AU2005204369B2 (en) | 2010-06-10 |
| JP2007517887A (ja) | 2007-07-05 |
| AP2006003659A0 (en) | 2006-06-30 |
| CN1946720A (zh) | 2007-04-11 |
| WO2005067900A3 (en) | 2005-09-29 |
| NZ548375A (en) | 2010-07-30 |
| OA13357A (en) | 2007-04-13 |
| KR20060121289A (ko) | 2006-11-28 |
| US7439374B2 (en) | 2008-10-21 |
| EP1709047A2 (en) | 2006-10-11 |
| TW200528459A (en) | 2005-09-01 |
| WO2005067900A2 (en) | 2005-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR047367A1 (es) | Compuestos de tiourea sustituidos con azabenzofurano, inhibidores de replicacion viral | |
| CA3095494C (en) | Modulators of proteolysis and associated methods of use | |
| AR127309A2 (es) | Derivados de piridazinona | |
| AR049126A1 (es) | Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing. | |
| AR049388A1 (es) | Heterociclos como inhibidores de aldosterona sintasa | |
| EA201190119A1 (ru) | ПРОИЗВОДНЫЕ ТРИАЗОЛОПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ МАР-КИНАЗЫ p38 | |
| AR067327A1 (es) | Derivados de piperidina / piperazina | |
| AR055360A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
| PE20060570A1 (es) | Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10 | |
| CY1112006T1 (el) | Μακροκυκλικοι αναστολεις του ιου της ηπατιτιδας c | |
| JP2013533317A5 (es) | ||
| AR046244A1 (es) | Activadores de glucoquinasa heteroaromaticos de seis miembros 5- sustituidos | |
| EA201791254A1 (ru) | Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| PE20060871A1 (es) | Compuestos de piridazinona | |
| AR071452A1 (es) | Inhibidores de hsp90 | |
| AR061101A1 (es) | Compuesto de fenil-triazolil- metoxi- arilo, su uso para la manufactura de un medicamento y composicion farmaceutica que lo comprende | |
| PE20030062A1 (es) | Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| RU2009148336A (ru) | Гетероциклические соединения в качестве положительных модуляторов метаботропного глутаматного рецептора 2 (рецептора mglu2) | |
| ES2570127T3 (es) | Compuestos y composiciones como inhibidores de la proteína quinasa | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| NO20081074L (no) | Macrocyclisk inhibitorer av hepatitis C-virus | |
| CA2536182A1 (en) | Macrocyclic peptides active against the hepatitis c virus | |
| PE20171342A1 (es) | Compuestos y su uso como inhibidores de bace |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |